AI Article Synopsis
- This study looked at how using a special computer system called Clinical Decision Support System (CDSS) can help doctors when making plans for treating cancer patients.
- They found that meeting with doctors from different areas (multidisciplinary team meetings) is really important for planning therapy.
- Although CDSS works well for many types of cancer, there's still more research needed to see how effective it really is in helping doctors make decisions.
Article Abstract
Background: For therapy planning in cancer patients multidisciplinary team meetings (MDM) are mandatory. Due to the high number of cases being discussed and significant workload of clinicians, Clinical Decision Support System (CDSS) may improve the clinical workflow.
Methods: This review and meta-analysis aims to provide an overview of the systems utilized and evaluate the correlation between a CDSS and MDM.
Results: A total of 31 studies were identified for final analysis. Analysis of different cancers shows a concordance rate (CR) of 72.7% for stage I-II and 73.4% for III-IV. For breast carcinoma, CR for stage I-II was 72.8% and for III-IV 84.1%, P≤ 0.00001. CR for colorectal carcinoma is 63% for stage I-II and 67% for III-IV, for gastric carcinoma 55% and 45%, and for lung carcinoma 85% and 83% respectively, all P>0.05. Analysis of SCLC and NSCLC yields a CR of 94,3% and 82,7%, P=0.004 and for adenocarcinoma and squamous cell carcinoma in lung cancer a CR of 90% and 86%, P=0.02.
Conclusion: CDSS has already been implemented in clinical practice, and while the findings suggest that its use is feasible for some cancers, further research is needed to fully evaluate its effectiveness.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584147 | PMC |
| http://dx.doi.org/10.3389/fonc.2023.1224347 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing the cumulative cisplatin dose for concurrent chemoradiotherapy beneficiaries among elderly nasopharyngeal carcinoma patients: a real world study.
Sci Rep
December 2024
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, Guangdong, China.
This study aimed to find a safe and effective cumulative cisplatin dose (CCD) for concurrent chemoradiotherapy (CCRT) beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients. A total of 765 elderly (≥ 60 years old) NPC patients treated with cisplatin-based CCRT and IMRT-alone from 2007 to 2018 were included in this study. RPA-generated risk stratification was used to identify CCRT beneficiaries.
View Article and Find Full Text PDFFirst study on the efficiency of Tc-rituximab for sentinel lymph node mapping and biopsy in oral squamous cell carcinoma.
Ann Nucl Med
December 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Objective: To explore the clinical efficiency of using the sentinel lymph node (SLN) imaging agent Tc-rituximab for lymphoscintigraphy and SLN biopsy (SLNB) in oral squamous cell carcinoma (OSCC) patients.
Methods: A retrospective study was conducted on 23 patients with OSCC who underwent Tc-rituximab lymphoscintigraphy and SLNB. The cohort comprised 16 men (69.
Radiographic Evaluation of the Prevalence of External Root Resorption in Patients With Periodontitis in Indore: A Cross-Sectional Study.
Cureus
November 2024
Department of Orthodontics and Dentofacial Orthopedics, Government College of Dentistry, Indore, IND.
Objective Permanent teeth roots undergo resorption under pathologic conditions such as trauma, orthodontic treatment, pulpal infections, periodontitis, and periodontal therapy. The present study aimed to determine the prevalence of external root resorption (ERR) in patients with periodontitis as seen in orthopantomography (OPGs). Methodology This single-center, retrospective, cross-sectional radiographic study was conducted from January 2021 to December 2022, including 656 orthopantomographs (OPGs) from patients with periodontitis.
View Article and Find Full Text PDFFollow-up performance of patients with cutaneous melanoma: recommendations for an effective strategy.
Wiad Lek
December 2024
STATE INSTITUTION OF SCIENCE ≪CENTER OF INNOVATIVE HEALTHCARE TECHNOLOGIES≫ STATE ADMINISTRATIVE DEPARTMENT, KYIV, UKRAINE; STATE INSTITUTION ≪NATIONAL SCIENTIFIC CENTER OF SURGERY AND TRANSPLANTATION NAMED AFTER O. O. SHALIMOV TO NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE≫, KYIV, UKRAINE.
Objective: Aim: To investigate the incidence of progression and median time for metastasizing, the development of recurrent localization, and to identify localizations with a high tendency to recurrence of melanoma during 10 years of patient follow-up observation.
Patients And Methods: Materials and Methods: The retrospective data of dynamic observation by dermatovenereologists of SIS ≪CIHT≫ SAD of 183 patients with skin melanoma for the period 2014 - first half of 2024.
Results: Results: Among 183 cases of melanoma, 23 cases (12,6%) were detected in stage III and 11 cases (6,0%) in stage IV, so the neglect rate was 18,6%.
Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn's disease management.
Therap Adv Gastroenterol
December 2024
Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Giustiniani, 2, Padua 35128, Italy.
Crohn's disease (CD) is a chronic, complex inflammatory disorder of the gastrointestinal tract that presents significant therapeutic challenges. Despite the availability of a wide range of treatments, many patients experience primary non-response, secondary loss of response, or adverse events, limiting the overall effectiveness of current therapies. Clinical trials often report response rates below 60%, partly due to stringent inclusion criteria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!